Almirall signs deal for Iktos’ AI technology in drug design
Spanish pharmaceutical firm Almirall has agreed with Iktos to leverage the latter’s generative...
Focus:
-
![AI bispecific small molecule drugs]()
Exscientia Q&A: leveraging AI to create bispecific small molecule drugs
-
![US CRISPR patents]()
USPTO reverses decision regarding interfering CRISPR patents
-
![Clinical trials of the future]()
Veeva R&D summit: unifying across clinical, regulatory and quality suites
-
![dassault medidata acquisition]()
Dassault to enhance clinical tech with $5.8bn Medidata acquisition
-
![ProAmpac CRREO]()
ProAmpac updates child-resistant pouch product line
Most Read
- Exscientia Q&A: leveraging AI to create bispecific small molecule drugs
- USPTO reverses decision regarding interfering CRISPR patents
- Veeva R&D summit: unifying across clinical, regulatory and quality suites
- Dassault to enhance clinical tech with $5.8bn Medidata acquisition
- ProAmpac updates child-resistant pouch product line
Latest Content
Almirall signs deal for Iktos’ AI technology in drug design
Spanish pharmaceutical firm Almirall has agreed with Iktos to leverage the latter’s generative modelling artificial intelligence (AI) technology to design novel drugs.
Huber Again Invests in the Future
Peter Huber Kältemaschinenbau AG has marked the official construction commencement for another expansion of its headquarters in Offenburg-Elgersweier with a ground-breaking ceremony.
Exscientia Q&A: leveraging AI to create bispecific small molecule drugs
Creating bispecific small molecule drugs poses huge challenges, but Exscientia has successfully used AI to automate drug discovery and optimise drug design for these complex compounds. Exscientia’s CEO Andrew Hopkins discusses the importance of AI in overcoming development challenges and why targeting two targets simultaneously is efficacious in certain complex diseases.
Pneumatic Conveying Equipment for Aerosol
Industrial sieving with the Russell Compact Airswept Sieve minimises the risk of contamination when screening in batches.
Are M&As the Key to Securing Growth in the Orphan Drugs Sector?
The orphan drug market can be an alluringly lucrative sector. Most big pharma corporations inherit these specialty business units through mergers and acquisitions (M&As). Yet it is not a viable sector for all pharmaceutical companies as it requires specialist capabilities.
USPTO reverses decision regarding interfering CRISPR patents
The Patient Trial and Appeal Board (PTAB) of the US Patent and Trademark Office (USPTO) has changed its stance regarding an interference between ten patent applications from the University of California (UC) and 13 of the Broad Institute’s patents, as well as one patent application, related to CRISPR-Cas9 genome editing in eukaryotic cells.
Veeva R&D summit: unifying across clinical, regulatory and quality suites
Veeva’s Vault platform aims to unify the clinical, regulatory and quality approaches used by pharma companies when bringing a drug to market. What are the benefits and challenges of this integrated approach?
Dassault to enhance clinical tech with $5.8bn Medidata acquisition
Product lifecycle management company Dassault Systèmes has announced it will acquire clinical cloud solution provider Medidata Solutions in an all-cash transaction.
Newly identified HA binding site could prove useful for universal influenza vaccine development
Because the new area of focus is conserved across several influenza viral strains, similar to the HA stem, it has the potential to become an additional attractive target for universal influenza vaccine design.
New Sterile Cleanroom PPE For USP 800 Compliance
With the US Pharmacopoeia (USP) 800 compliance deadline coming up this year, many cleanroom operators are scrambling to find the proper sterile cleanroom products.
Latest News
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.
Close
Close
Close
Go Top
